Figure 5 is a DNA sequence encoding the gp120 envelope polypeptide of WEAU1.6 (SEQ ID NO: 7),

Figure 6A-6D sets out the envelope polypeptide sequences of 92UG046-T8 (SEQ ID NO: 10), 93UG086-T8 (SEQ ID NO: 12), 92US077-T8 (SEQ ID NO: 14), 93US143-T8 (SEQ ID NO: 16), 96USHIPS4-T8 (SEQ ID NO: 18, 96USHIPS9-T8(SEQ ID NO: 20), 96USSN20-T8 (SEQ ID NO: 22), HXB2 (SEQ ID NO: 6; a prototype CD4-tropic HIV-1 virus) and AD3.v6 (SEQ ID NO: 2); wherein the sequences displayed consist of the full length envelope polypeptides (gp120 and gp41) and the residue where the gp120 polypeptide ends is clearly indicated in the figure;

Figure 7 is a DNA sequence encoding the gp120 envelope polypeptide of 92UG046-T8 (SEQ ID NO: 9);

Figure 8 is a DNA sequence encoding the gp120 envelope polypeptide of 93UG086-T8 (SEQ ID NO: 11);

Figure 9 is a DNA sequence encoding the gp120 envelope polypeptide of 92US077-T8 (SEQ ID NO: 13);

Figure10 is a DNA sequence encoding the gp120 envelope polypeptide of 93US143-T8 (SEQ ID NO: 15);

Figure 11 is a DNA sequence encoding the gp120 envelope polypeptide of 96USHIPS4-T8 (SEQ ID NO: 17);

Figure 12 is a DNA sequence encoding the gp120 envelope polypeptide of 96USHIPS9-T8 (SEQ ID NO: 19); and

Figure ~~8~~ 13 is a DNA sequence encoding the gp120 envelope polypeptide of 96USSN20-T8 (SEQ ID NO: 21).

JC 1/25/05

Detailed Description of the Invention

The present invention is illustrated by the following examples relating to CD8-tropic HIV-1. Example 1 describes experiments demonstrating the ability of HIV-1 viruses AD3.v6 and AD3.v22 to infect CD8-positive peripheral blood lymphocytes. In Examples 2 and 3, respectively, AD3.v6 and AD3.v22 are shown to use CD8 receptors to infect a CD8-positive, CD4-negative T cell line and to infect CD8-transfected HeLa and COS cell lines. Example 4 describes the ability of anti-CD8